Mesenchymal stem cell therapy in the treatment of hip osteoarthritis

Rodrigo Mardones, Claudio M. Jofré, L. Tobar, José J. Minguell


Published: 19 March 2017   Article history

Abstract

This study was performed to investigate the safety and efficacy of the intra-articular infusion of *ex vivo* expanded autologous bone marrow–derived mesenchymal stem cells (BM–MSC) to a cohort of patients with articular cartilage defects in the hip. The above rationale is sustained by the notion that MSCs express a chondrocyte differential potential and produce extracellular matrix molecules as well as regulatory signals, that may well contribute to cure the function of the damaged hip joint. A cohort of 10 patients with functional and radiological evidences of hip osteoarthritis, either in one or both legs, was included in the study. BM–MSC (the cell product) were prepared and infused into the damaged articulation(s) of each patient (60 × 10⁶ cells in 3 weekly/doses). Before and after completion of the cell infusion scheme, patients were evaluated (hip scores for pain, stiffness, physical function, range of motion), to assess whether the infusion of the respective cell product was beneficial. The intra-articular injection of three consecutive weekly doses of *ex vivo* expanded autologous BM–MSC to...
INTRODUCTION

Osteoarthritis (OA) embodies a recurrent and incapacitating arthritic condition, characterized by the occurrence of damaging joint changes, including cartilage destruction by cytokines, matrix metalloproteinases and prostaglandins. As a consequence, a cascade of deleterious events starts, including subchondral bone remodeling and resorption, hypertrophic differentiation of chondrocytes, neovascularization of synovial tissue and focal joint cartilage calcification. Management of OA has been diverse and included pharmacological therapy treatment options, surgical interventions and orthopedic procedures including total joint replacement and/or joint fusion [1, 2].

Recent advances in regenerative medicine, particularly the optimization of procedures associated with the utilization of stem and progenitor cells, has opened new therapeutic perspectives for the treatment of OA. Given that articular cartilage exhibits little or no ability for self-repair, the option to delivery into the OA injured site a source of progenitor cells capable to differentiate into chondrocytes, appears to be an attractive therapeutic option [3–6].

Mesenchymal stem cells (MSCs) fulfill the above requirements. In addition to differentiate into chondrocytes (which in turn produce and maintain a cartilaginous matrix), MSC produce and secrete a vast array of mediators of cell function, like growth factor and cytokines. And last but not least, the minute number of ‘native’ MSC present in several adult tissues, including the bone marrow, can be easily increased by ex vivo procedures [7].
the function of a damaged joint.

**MATERIALS AND METHODS**

**Patient population**

The study was performed at Clinica Las Condes, Santiago, Chile. Clinica Las Condes is affiliated to Johns Hopkins Medicine International and accredited by the Joint Commission International (USA). Procedures carried out in this study were in compliance with regulations established by the Research and Ethics Committees of Clinica Las Condes.

A total of 10 patients with osteoarthritis in one or both hips were enrolled in the study. Main inclusion criteria included age $\geq 60$ years, radiological evidence of osteo-degenerative disease changes (level to moderate) in one or both joint hip(s) and pain levels (refractory to analgesics and/or hyaluronic acid or cortisone injection treatment) $\geq 40$ (Visual Analog Scale of 100 mm).

Main exclusion criteria included evidence of intra-articular space $\leq 1$ mm, indication of cartilage’s loss of volume, as measured by magnetic resonance imaging and/or failure to complete the protocol’s established number of cell infusions. Clinical characteristics of the study population are given in Table I.

**Table I.**

Clinical characteristics of the study population at inclusion

<table>
<thead>
<tr>
<th>Patient characteristics (initials/sex/age)</th>
<th>Comorbidities</th>
<th>Concomitant drug(s) intake</th>
<th>Hip damage location</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPB/f/57</td>
<td>hypothyroidism, arrhythmia, arterial hypertension</td>
<td>Atenolol, Zopiclone, Levothyroxine</td>
<td>right</td>
</tr>
<tr>
<td>MMP/f/54</td>
<td>hypothyroidism, cervical dysplasia</td>
<td>Syndol, Tramadol</td>
<td>right</td>
</tr>
<tr>
<td>DCF/m/60</td>
<td>none</td>
<td>none</td>
<td>right</td>
</tr>
<tr>
<td>ALH/m/50</td>
<td>dyslipidemia, hypothyroidism</td>
<td>Levothyroxine</td>
<td>right</td>
</tr>
</tbody>
</table>

### Patient characteristics

<table>
<thead>
<tr>
<th>Initials/sex/age</th>
<th>Comorbidities</th>
<th>Concomitant drug(s)</th>
<th>Hip damage location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOP/f/54</td>
<td>hypothyroidism, asthma, arterial hypertension</td>
<td>Levothyroxine, Losartan, Budesonide</td>
<td>right</td>
</tr>
<tr>
<td>PVV/f/51</td>
<td>none</td>
<td>none</td>
<td>right</td>
</tr>
<tr>
<td>FVS/m/24</td>
<td>none</td>
<td>none</td>
<td>left</td>
</tr>
<tr>
<td>KOV/f/59</td>
<td>asthma, arterial hypertension, dyslipidemia</td>
<td>Atenolol, Desloratadine</td>
<td>right and left</td>
</tr>
<tr>
<td>JPD/m/49</td>
<td>mood disorder</td>
<td>Sertraline</td>
<td>right and left</td>
</tr>
<tr>
<td>SPS/m/39</td>
<td>none</td>
<td>Sibutramine</td>
<td>right and left</td>
</tr>
</tbody>
</table>

### Study end points

Primary endpoint included the feasibility to prepare from each patient a viable population of $60 \times 10^6$ ex vivo expanded bone marrow-derived (BM)-MSC. Secondary endpoints included clinical evidence(s) confirming that the infusion of the cell product into the damaged hip(s) was safe and proficient to generate a slowdown in the progression of osteoarthritis.

### Preparation of ex vivo expanded autologous BM-MSC

For preparation of BM-MSC, all patients underwent bone marrow aspiration (30 ml) from the posterior iliac crest. In the case of patients receiving BM-MSC infusion on both legs, the volume of bone marrow aspiration was 60 ml. Bone marrow aspirates were sent to the GMP facility for isolation and ex vivo expansion of bone marrow-resident MSC.

Shortly, the ex vivo expansion procedures included, (i) processing of bone marrow aspirates by density separation to isolate a fraction of mononuclear cells (BM-MNC), and b) the expansion, by means of cell culture procedures, of the minor population of ‘native’ MSC present in BM-MNC [7, 8]. At the end of the expansion procedures, the resulting population of autologous BM-MSC (the cell product) was assessed for cell number, viability, microbiological condition and expression of distinctive MSC cell membrane markers [9]. In addition, flow cytometry analysis proved that the ex vivo manipulations did not triggered changes in MSC’s attributes [10].

### Cell infusion
Subsequently, the damaged hip(s) of each patient received the infusion of $20 \times 10^6 \text{ex vivo}$ expanded BM–MSC. After 7 and 14 consecutive days, patients received the infusion of a second and a third dose of the respective cell product \cite{4, 11}. Thus, within a period of 14 days, the damaged hip(s) of each patient received the infusion of $60 \times 10^6 \text{ex vivo}$ expanded autologous MSC.

**Clinical outcome assessment**

Clinical data were prospectively collected during the study period (May 2013 to September 2016) and included evaluation of pain, stiffness, physical function and range of motion. For this, the following specific scores were used: Harris Hip (HHS), Visual Analog (VAS), Vail Hip and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Additionally, Tonnis X-ray measurements of the hip joint(s) were performed to evaluate changes in the progression of osteoarthritis \cite{5, 11, 12}.

**RESULTS**

**Preparation and infusion of ex vivo expanded bone marrow-derived autologous MSC**

After bone marrow aspiration, no bleeding, infection and/or other complications were identified. In turn, \textit{ex vivo} expanded autologous BM–MSCs manufactured for all patients, fulfilled the established rigorous release criteria for infusion \cite{9, 10}. Accordingly, the infusion of the autologous cell product (three doses per damaged hip) was well tolerated and no complications and/or adverse events occurred post-infusion.

**Clinical outcome**

To assess whether the infusion of the cell product was beneficial patients were tested before and at different times after completing the cell infusion schedule. As shown in Table II, raw data analysis using a cartilage injury evaluation package, indicated that in all patients the infusion of the cell product bring about an improvement in pain, function and range of motion during the follow-up period of 16–40 months after cell infusion. The statistical significance of the above data is shown in Table III. In line with this observation, the
radiographic scores (Tönnis Classification of Osteoarthritis) of the damaged leg(s) remained without variation in all patients, except one (SPS), after the administration of the cell product (Table II).

**Table II.**
Clinical outcomes after MSC infusion by using a cartilage injury evaluation package including pain, function, range of motion and radiographic evaluation

<table>
<thead>
<tr>
<th>Patient</th>
<th>Leg treated</th>
<th>VASC</th>
<th>WOMAC</th>
<th>HHSM</th>
<th>VAIL</th>
<th>Tonnis</th>
<th>Last follow up (mon after infusion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KOV</td>
<td>L</td>
<td>3</td>
<td>0</td>
<td>21</td>
<td>4</td>
<td>66</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>2</td>
<td>0</td>
<td>10</td>
<td>4</td>
<td>10</td>
<td>78</td>
</tr>
<tr>
<td>SPS</td>
<td>L</td>
<td>4</td>
<td>2</td>
<td>13</td>
<td>13</td>
<td>69</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>95</td>
<td>100</td>
</tr>
<tr>
<td>RPB</td>
<td>R</td>
<td>5</td>
<td>2</td>
<td>70</td>
<td>51</td>
<td>72</td>
<td>83</td>
</tr>
<tr>
<td>ALH</td>
<td>L</td>
<td>6</td>
<td>1</td>
<td>89</td>
<td>74</td>
<td>72</td>
<td>96</td>
</tr>
<tr>
<td>MMP</td>
<td>R</td>
<td>8</td>
<td>2</td>
<td>51</td>
<td>30</td>
<td>40</td>
<td>75</td>
</tr>
<tr>
<td>PVV</td>
<td>L</td>
<td>4</td>
<td>2</td>
<td>40</td>
<td>32</td>
<td>63</td>
<td>62</td>
</tr>
<tr>
<td>FVS</td>
<td>L</td>
<td>4</td>
<td>0</td>
<td>12</td>
<td>10</td>
<td>68</td>
<td>100</td>
</tr>
<tr>
<td>MOP</td>
<td>R</td>
<td>5</td>
<td>3</td>
<td>82</td>
<td>14</td>
<td>36</td>
<td>72</td>
</tr>
<tr>
<td>DCF</td>
<td>R</td>
<td>6</td>
<td>1</td>
<td>34</td>
<td>13</td>
<td>62</td>
<td>83</td>
</tr>
<tr>
<td>JPD</td>
<td>L</td>
<td>2</td>
<td>0</td>
<td>8</td>
<td>0</td>
<td>82</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>4</td>
<td>0</td>
<td>16</td>
<td></td>
<td>70</td>
<td>96</td>
</tr>
</tbody>
</table>

**a** initials;  
**b** L, left; R, right;  
**c** pain scale;
Table III.

Statistical significance of the clinical effects elicited by the infusion of ex vivo expanded autologous BM-MSC into patients with hip osteoarthritis

<table>
<thead>
<tr>
<th></th>
<th>Pre-infusion values (mean ± SEM)</th>
<th>Post-infusion values (mean ± SEM)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS</td>
<td>4.2 ± 0.5</td>
<td>1.1 ± 0.3</td>
<td>0.0001</td>
</tr>
<tr>
<td>WOMAC</td>
<td>34.5 ± 8.2</td>
<td>19.2 ± 6.1</td>
<td>0.15</td>
</tr>
<tr>
<td>HHSM</td>
<td>61.9 ± 6.1</td>
<td>85.7 ± 3.9</td>
<td>0.003</td>
</tr>
<tr>
<td>VAIL</td>
<td>61.2 ± 4.5</td>
<td>78.2 ± 5.2</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Several techniques, including micro fracture, autologous chondrocyte implantation, and mosaicplasty have been used for the treatment of symptomatic chondral lesions in the hip. Nevertheless, to date there is still no definitive solution to reproducibly replicate the load-bearing capacity and durability of native joint cartilage [1, 2, 4]. Consequently, new therapeutic options based in the use of MSC have been initiated.

Even though strong evidences indicate that clinical use of MSC is feasible and safe [4, 5], confirmation for their clinical efficacy still remain controversial [13–15].

The results presented in this clinical study, revealed that shortly after the intra articular infusion of a cell product consisting of ex vivo expanded autologous BM-MSC, an improvement in hip function occurred. The reparative effect, which is fully maintained over time (Table II), proved to be free of major complications or side effects during the prolonged follow-up period. Moreover, the radiographic scores of the hip joint(s), assessed on a time period ranging from 7 to 30 months after cell infusion, clearly demonstrate a halt in the progression of osteoarthritis.
It seems likely that the distinctiveness of this clinical study, as compared to others \[3, 15\], may well reside in the two following attributes, (i) the \textit{ex vivo} MSC expansion procedure employed in this study, privileged quality than quantity of cell product to be administered to the patient \[9, 10\], and (ii) based in previous observations, the cell product was administered to the patient, instead of 1 in 3 consecutive weekly doses \[4–11\]. Further studies will contribute to validate and confirm the above statements.

**ACKNOWLEDGEMENTS**

We would like to acknowledge the dedicated contribution of clinicians researchers, and nurses at the Centro de Terapia Regenerativa Celular and Centro de Traumatología y Ortopedia, Clínica Las Condes, Santiago, Chile.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**


2 Thysen S, Luyten FP, Lories RJ. Targets, models and challenges in osteoarthritis research. \textit{Dis Model Mech} 2015; 8: 17–30. [Google Scholar] [Crossref] [PubMed]


4 Mardones R, Larrain C. Cartilage restoration technique of the hip. \textit{J Hip Preservation Surgery} 2015; 3: 30–6. [Google Scholar] [Crossref]

5 Jo CH, Lee YG, Shin WH et al. Intra-articular injection of mesenchymal stem cells for the


Google Scholar  Crossref  PubMed


Google Scholar  Crossref  PubMed

© The Author 2017. Published by Oxford University Press

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
More on this topic

Efficacy of a non-image-guided diagnostic hip injection in patients with clinical and radiographic evidence of intra-articular hip pathology

Previous failed hip arthroscopy negatively impacts early patient-reported outcomes of the periacetabular osteotomy: an ANCHOR Matched Cohort Study

Higher patient activity level and subchondral stiffening in asymptomatic cam femoroacetabular impingement subjects

Medial synovial fold cyst in the hip leading to pectineofoveal impingement

Related articles in PubMed

Remote Ischemic Preconditioning Acutely Improves Coronary Microcirculatory Function.

Porphyrin-Based SOD Mimic MnTnBu OE -2-PyP5+ Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis.

The Cellular Biology of Fracture Healing.

Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.

Citing articles via

https://academic.oup.com/jhps/article/4/2/159/3074996
Simultaneous pigmented villonodular synovitis and synovial chondromatosis of the hip: case report

Impact, impact, impact

What the papers say

Quadratus lumborum block provides improved immediate postoperative analgesia and decreased opioid use compared with a multimodal pain regimen following hip arthroscopy

The education and training of future hip preservation surgeons: aggregate recommendations of high-volume surgeons